-
Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its 20-valent pneumococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent infectious diseases caused by…
-
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China, has entered into a strategic agreement with UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) and the Daxing district government of Beijing. The collaboration is focused on the vaccine sector, aiming to introduce new vaccines to the…
-
Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the signing of an authorized agency and technical transfer cooperation agreement with a company based in Bangladesh. The undisclosed Bangladeshi company will collaborate with Kangtai Bio on the 23-valent pneumococcal polysaccharide vaccine semi-finished stock solution. The…
-
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector, has entered into a supply and production licensing agreement with a leading pharmaceutical company based in Bahrain. This partnership focuses on a range of vaccines, including the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal…
-
Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into an agency and technology transfer agreement with Egyptian firm Gennvax Egypt concerning Kangtai’s 13-valent pneumococcal polysaccharide conjugate vaccine. Under the terms of the agreement, the two companies will collaborate to advance the marketing approval of…
-
Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into licensing agreements with undisclosed pharmaceutical companies in Pakistan and India. These strategic partnerships aim to strengthen the regulatory filing, marketing, and distribution of Kangtai Bio’s varicella attenuated live vaccines in both countries. Vaccine Description and…
